Olanzapine-Induced Neuroleptic Malignant Syndrome With Mental Retardation

Margolese, Howard C.; Chouinard, Guy

doi:10.1176/ajp.156.7.1115a

Cited by 29 publications

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Olanzapine associated weight gain, Hyperglycemia and Neuroleptic Malignant Syndrome: case report

Malyuk

Gibson

Procyshyn

et al. 2002

Int J Geriat Psychiatry

View full text Add to dashboard Cite

We describe here a case of olanzapine associated weight gain, hyperglycemia and neuroleptic malignant syndrome in a 64 year-old woman with a significant medical history. Eighteen weeks after initiating olanzapine, Mrs X lost glycemic control, exhibited signs and symptoms consistent with neuroleptic malignant syndrome and gained 8.9 kg. We suggest that utilization of olanzapine in the less medically stable geriatric patient be implemented with vigilant monitoring for such complications mentioned above.

show abstract

Olanzapine associated weight gain, Hyperglycemia and Neuroleptic Malignant Syndrome: case report

Malyuk

Gibson

Procyshyn

et al. 2002

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

Olanzapine induced neuroleptic malignant syndrome—a case review

Kogoj

Velikonja

2003

Human Psychopharmacology

View full text Add to dashboard Cite

Neuroleptic malignant syndrome is the rarest and the most serious of the neuroleptic induced movement disorders. Although potent neuroleptics are more frequently associated with NMS, atypical antipsychotic drugs may also be a cause of NMS. Three databases were searched using the terms 'olanzapine' and 'neuroleptic' 'malignant syndrome'. Case reports were selected and reviewed from among all articles that fulfilled the search criteria. Twenty six cases were reviewed. Twenty cases fulfilled the criteria published by Sachdev et al. Olanzapine was the most probable cause of NMS in 16 cases. The absence of rigidity was described in only two of 16 highly probable olanzapine induced NMS cases, which is not as often as it is reported in clozapine associated NMS (36%). It was found that prior NMS is an important risk factor in NMS.

show abstract

Reviewing the use of antipsychotic drugs in people with intellectual disability

Malfa

Lassi

Bertelli

et al. 2006

Hum. Psychopharmacol. Clin. Exp.

View full text Add to dashboard Cite

Randomised controlled trials and systematic reviews would be the golden standard for therapeutical studies; unfortunately they are really few in this field. It is anyway significative that all the studies reported focus on the use of antipsychotics in people with intellectual disability presenting behavioural problems. To increase the validity of these studies it is recommendable to proceed only with well-designed studies, possibly double-blind versus placebo or other medications. There is need to define precise inclusion criteria, precise symptomatological or behavioural targets and adaptative ability assessment, using valid and reliable diagnostic instruments.

show abstract

Olanzapine-Induced Neuroleptic Malignant Syndrome With Mental Retardation

Cited by 29 publications

References 6 publications

Olanzapine associated weight gain, Hyperglycemia and Neuroleptic Malignant Syndrome: case report

Olanzapine associated weight gain, Hyperglycemia and Neuroleptic Malignant Syndrome: case report

Olanzapine induced neuroleptic malignant syndrome—a case review

Reviewing the use of antipsychotic drugs in people with intellectual disability

Contact Info

Product

Resources

About